These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12587394)

  • 1. [Probabilities of controlling tumors and complications (TCP/NTCP) after radiotherapy: methodologic, physical, and biological aspects].
    Kulik C; Mazurier J; Lartigau E
    Cancer Radiother; 2002 Nov; 6 Suppl 1():155s-165s. PubMed ID: 12587394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCP and NTCP in preclinical and clinical research in Europe.
    Baumann M; Petersen C; Krause M
    Rays; 2005; 30(2):121-6. PubMed ID: 16294904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-adaptive optimization: selective boosting of high-risk tumor subvolumes.
    Kim Y; Tomé WA
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1528-42. PubMed ID: 17126211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiobiological impact of reduced margins and treatment technique for prostate cancer in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP).
    Jensen I; Carl J; Lund B; Larsen EH; Nielsen J
    Med Dosim; 2011; 36(2):130-7. PubMed ID: 20488692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can dose-response models predict reliable normal tissue complication probabilities in radical radiotherapy of urinary bladder cancer? The impact of alternative radiation tolerance models and parameters.
    Muren LP; Jebsen N; Gustafsson A; Dahl O
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):627-37. PubMed ID: 11395229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of radiation-induced normal tissue complications in radiotherapy using functional image data.
    Nioutsikou E; Partridge M; Bedford JL; Webb S
    Phys Med Biol; 2005 Mar; 50(6):1035-46. PubMed ID: 15798307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer.
    Muren LP; Maurstad G; Hafslund R; Anker G; Dahl O
    Radiother Oncol; 2002 Feb; 62(2):173-83. PubMed ID: 11937244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability.
    Mackay RI; Hendry JH
    Radiother Oncol; 1999 Jan; 50(1):67-75. PubMed ID: 10225559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inverse and forward optimization of one- and two-dimensional intensity-modulated radiation therapy-based treatment of concave-shaped planning target volumes: the case of prostate cancer.
    Corletto D; Iori M; Paiusco M; Brait L; Broggi S; Ceresoli G; Iotti C; Calandrino R; Fiorino C
    Radiother Oncol; 2003 Feb; 66(2):185-95. PubMed ID: 12648791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A method to visualize the uncertainty of the prediction of radiobiological models.
    Zhang L; Hub M; Thieke C; Floca RO; Karger CP
    Phys Med; 2013 Sep; 29(5):556-61. PubMed ID: 23260766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction of radiobiological models as TCP (tumor control probability) and NTCP (normal tissue complication probability): from dose to clinical effects prediction].
    Chaikh A; Thariat J; Thureau S; Tessonnier T; Kammerer E; Fontbonne C; Dubray B; Balosso J; Fontbonne JM
    Cancer Radiother; 2020 Jun; 24(3):247-257. PubMed ID: 32220563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The determination of the optimal irradiation dose in the tumor tissue-normal body tissues system].
    Klepper LIa
    Med Tekh; 1997; (4):18-21. PubMed ID: 9379858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological mechanisms of normal tissue damage: importance for the design of NTCP models.
    Trott KR; Doerr W; Facoetti A; Hopewell J; Langendijk J; van Luijk P; Ottolenghi A; Smyth V
    Radiother Oncol; 2012 Oct; 105(1):79-85. PubMed ID: 22748390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of normal tissue complication probability models in the clinic.
    Marks LB; Yorke ED; Jackson A; Ten Haken RK; Constine LS; Eisbruch A; Bentzen SM; Nam J; Deasy JO
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3 Suppl):S10-9. PubMed ID: 20171502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
    Luxton G; Hancock SL; Boyer AL
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCP and NTCP: a basic introduction.
    Baumann M; Petersen C
    Rays; 2005; 30(2):99-104. PubMed ID: 16294901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose selection for optimal treatment results and avoidance of complications.
    Nagano H; Nakayama S; Shuto T; Asada H; Inomori S
    Prog Neurol Surg; 2009; 22():11-19. PubMed ID: 18948715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods for Reducing Normal Tissue Complication Probabilities in Oropharyngeal Cancer: Dose Reduction or Planning Target Volume Elimination.
    Samuels SE; Eisbruch A; Vineberg K; Lee J; Lee C; Matuszak MM; Ten Haken RK; Brock KK
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):645-52. PubMed ID: 27681761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
    King CR; DiPetrillo TA; Wazer DE
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complication probability as assessed from dose-volume histograms.
    Lyman JT
    Radiat Res Suppl; 1985; 8():S13-9. PubMed ID: 3867079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.